Compare HDFC Bank Limited Common Stock (HDB) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HDFC Bank Limited Common Stock vs Tango Therapeutics Inc. — how do they compare? HDFC Bank Limited Common Stock trades at $23.19 (market cap $115.00B), while Tango Therapeutics Inc. trades at $22.3 (market cap $3.74B). The key difference: HDFC Bank Limited Common Stock is far larger — about 30.7× Tango Therapeutics Inc.'s market cap, and HDFC Bank Limited Common Stock pays a 1.81% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold HDFC Bank Limited Common Stock for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| HDB | TNGX | |
|---|---|---|
Market Cap | $115.00B | $3.74B |
Volume | 5,621,803 | 3,438,781 |
Sector | Financials | Health |
52-Week High | $37.18 | $32.90 |
52-Week Low | $21.84 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $14.49T | $2.76B |
Dividend Yield | 1.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDFC Bank (HDB) trades at $22.76, up 0.8% with neutral technical indicators. The bank maintains strong profitability with 28.24% net income margin and consistent earnings beats. However, significant legal headwinds emerge as multiple class action lawsuits approach deadlines in October 2026, creating investor uncertainty despite solid fundamentals.
While HDB demonstrates financial strength with improving debt-to-asset ratios and positive cash flow projections for 2026, the pending securities litigation represents a material risk. Analyst consensus leans cautious with 67% hold ratings, suggesting investors await legal clarity before more bullish positioning despite attractive valuation metrics.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About HDFC Bank Limited Common Stock
HDFC Bank provides retail, wholesale, and treasury banking services in India. Its offerings include deposits, lending, payments, trade finance, and financial services for individuals and businesses.
Read more on HDB →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
